Signal transducer and activator of transcription 3 - A promising target in colitis-associated cancer

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 2, 2014, Pages 551-560

  Pandurangan, Ashok Kumar ^a   Esa, Norhaizan Mohd ^a,b  

^a Faculty of Science   (Malaysia)

^b UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Colitis associated cancer; Cytokines; MiRNA; NF B; STAT3

Indexed keywords

ANTINEOPLASTIC AGENT; STAT3 PROTEIN;

ANIMAL; COLITIS; COLON TUMOR; DRUG ANTAGONISM; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; COLITIS; COLONIC NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; STAT3 TRANSCRIPTION FACTOR;

EID: 84894658138     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.2.551     Document Type: Review

References (140)

1. Abraham C, Cho J (2009). Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis, 15, 1090-100.
2. Aggarwal BB, Vijayalekshmi RV, Sung B (2009). Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res, 15, 425-30.
3. Armanious H, Gelebart P, Mackey J, et al (2010). STAT3 upregulates the protein expression and transcriptional activity of beta-catenin in breast cancer. Int J Clin Exp Pathol, 3, 654-64.
4. Ashokkumar P, Sudhandiran G (2008). Protective role of luteolin on the status of lipid peroxidation and antioxidant defense against azoxymethane-induced experimental colon carcinogenesis. Biomed Pharmacother, 62, 590-7.
5. Ashokkumar P, Sudhandiran G (2011). Luteolin inhibits cell proliferation during Azoxymethane-induced experimental colon carcinogenesis via Wnt/ beta-catenin pathway. Invest New Drugs, 29, 273-84.
6. Atreya R, Mudter J, Finotto S, et al (2000). Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med, 6, 583-8.
7. Atreya R, Neurath MF (2008). Signaling molecules: the pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer. Curr Drug Targets, 9, 369-74.
8. Bartel DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-97.
9. Baud V, Karin M (2009). Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov, 8, 33-40.
10. Becker C, Fantini MC, Schramm C, et al (2004). TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity, 21, 491-501.
11. Becker C, Fantini MC, Wirtz S, et al (2005). IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle, 4, 217-20.
12. Bernstein CN, Blanchard JF, Kliewer E, et al (2001). Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer, 91, 854-62.
13. Bollrath J, Phesse TJ, von Burstin VA, et al (2009). gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell, 15, 91-102.
14. Brand S (2009). Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut, 58, 1152-67.
15. Bray SJ (2006). Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol, 7, 678-89.
16. Bromberg JF, Wrzeszczynska MH, Devgan G, et al (1999). Stat3 as an oncogene. Cell, 98, 295-303.
17. Buettner R, Mora LB, Jove R (2002). Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res, 8, 945-54.
18. Caprioli F, Sarra M, Caruso R, et al (2008). Autocrine regulation of IL-21 production in human T lymphocytes. J Immunol, 180, 1800-7.
19. Carthew RW (2006). Gene regulation by microRNAs. Curr Opin Genet Dev, 16, 203-8.
20. Catlett-Falcone R, Landowski TH, Oshiro MM, et al (1999). Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 10, 105-15.
21. Chen Q, Wang H, Liu Y, et al (2012). Inducible microRNA-223 down-regulation promotes TLR-triggered IL-6 and IL-1beta production in macrophages by targeting STAT3. PLoS ONE, 7, 42971.
22. Corvinus FM, Orth C, Moriggl R, et al (2005). Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia, 7, 545-55.
23. Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 420, 860-7.
24. Danese S, Mantovani A (2010). Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene, 29, 3313-23.
25. Darnell JE, Jr (2002). Transcription factors as targets for cancer therapy. Nat Rev Cancer, 2, 740-9.
26. Dashwood RH, Suzui M, Nakagama H, et al (1998). High frequency of beta-catenin (ctnnb1) mutations in the colon tumors induced by two heterocyclic amines in the F344 rat. Cancer Res, 58, 1127-9.
27. De Nitto D, Sarra M, Pallone F, et al (2010). Interleukin-21 triggers effector cell responses in the gut. World J Gastroenterol, 16, 3638-41.
28. Deng L, Zhou JF, Sellers RS, et al (2010). A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. Am J Pathol, 176, 952-67.
29. Dill MT, Tornillo L, Fritzius T, et al (2013). Constitutive Notch2 signaling induces hepatic tumors in mice. Hepatology, 57, 1607-19.
30. Dontu G, Jackson KW, McNicholas E, et al (2004). Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res, 6, 605-15.
31. Fiala ES, Sohn OS, Hamilton SR (1987). Effects of chronic dietary ethanol on in vivo and in vitro metabolism of methylazoxymethanol and on methylazoxymethanol-induced DNA methylation in rat colon and liver. Cancer Res, 47, 5939-43.
32. Fina D, Sarra M, Fantini MC, et al (2008). Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology, 134, 1038-48.
33. Fre S, Pallavi SK, Huyghe M, et al (2009). Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine. Proc Natl Acad Sci U S A, 106, 6309-14.
34. Friedman RC, Farh KK, Burge CB, et al (2009). Most mammalian mRNAs are conserved targets of microRNAs. Genome Res, 19, 92-105.
35. Fujino S, Andoh A, Bamba S, et al (2003). Increased expression of interleukin 17 in inflammatory bowel disease. Gut, 52, 65-70.
36. Garg P, Sarma D, Jeppsson S, et al (2010). Matrix metalloproteinase-9 functions as a tumor suppressor in colitis-associated cancer. Cancer Res, 70, 792-801.
37. Genta RM (2003). The gastritis connection: prevention and early detection of gastric neoplasms. J Clin Gastroenterol, 36, 61-2.
38. Gregorieff A, Clevers H (2005). Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev, 19, 877-90.
39. Grivennikov S, Karin E, Terzic J, et al (2009). IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell, 15, 103-13.
40. Grivennikov S, Karin M (2008). Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell, 13, 7-9.
41. Harris TJ, Grosso JF, Yen HR, et al (2007). Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol, 179, 4313-7.
42. He G, Karin M (2011). NF-kappaB and STAT3-key players in liver inflammation and cancer. Cell Res, 21, 159-68.
43. He TC, Sparks AB, Rago C, et al (1998). Identification of c-MYC as a target of the APC pathway. Science, 281, 1509-12.
44. Heikkila K, Ebrahim S, Lawlor DA (2008). Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer, 44, 937-945.
45. Heitzler P, Bourouis M, Ruel L, et al (1996). Genes of the Enhancer of split and achaete-scute complexes are required for a regulatory loop between Notch and Delta during lateral signalling in Drosophila. Development, 122, 161-71.
46. Hirahara K, Ghoreschi K, Laurence A, et al (2010). Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev, 21, 425-34.
47. Hyun YS, Han DS, Lee AR, et al (2012). Role of IL-17A in the development of colitis-associated cancer. Carcinogenesis, 33, 931-6.
48. Iliopoulos D, Jaeger SA, Hirsch HA, et al (2010). STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell, 39, 493-506.
49. Itzkowitz SH, Yio X (2004). Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol, 287, 7-17.
50. Ivanov, II, McKenzie BS, Zhou L, et al (2006). The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell, 126, 1121-33.
51. Jensen J, Pedersen EE, Galante P, et al (2000). Control of endodermal endocrine development by Hes-1. Nat Genet, 24, 36-44.
52. Jin S, Mutvei AP, Chivukula IV, et al (2012). Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKKalpha/IKKbeta. Oncogene, 26, 517.
53. Johnson GE, Ivanov VN, Hei TK (2008). Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival. Apoptosis, 13, 790-802.
54. Jump RL, Levine AD (2004). Mechanisms of natural tolerance in the intestine: implications for inflammatory bowel disease. Inflamm Bowel Dis, 10, 462-78.
55. Kanai T, Nemoto Y, Kamada N, et al (2009). Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease. Curr Opin Gastroenterol, 25, 306-13.
56. Kargl J, Haybaeck J, Stancic A, et al (2013). O-1602, an atypical cannabinoid, inhibits tumor growth in colitis-associated colon cancer through multiple mechanisms. J Mol Med, 91, 449-58.
57. Karin M, Greten FR (2005). NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol, 5, 749-759.
58. Kathiria AS, Neumann WL, Rhees J, et al (2012). Prohibitin attenuates colitis-associated tumorigenesis in mice by modulating p53 and STAT3 apoptotic responses. Cancer Res, 72, 5778-89.
59. Kaur M, Velmurugan B, Tyagi A, et al (2010). Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of beta-catenin-dependent signaling. Neoplasia, 12, 415-24.
60. Kawada M, Seno H, Uenoyama Y, Set al (2006). Signal transducers and activators of transcription 3 activation is involved in nuclear accumulation of beta-catenin in colorectal cancer. Cancer Res, 66, 2913-7.
61. Kawanishi S, Hiraku Y, Pinlaor S, et al (2006). Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol Chem, 387, 365-72.
62. Kim JH, Kim JE, Liu HY, et al (2008). Regulation of interleukin-6-induced hepatic insulin resistance by mammalian target of rapamycin through the STAT3-SOCS3 pathway. J Biol Chem, 283, 708-15.
63. Kobayashi T, Okamoto S, Hisamatsu T, et al (2008). IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut, 57, 1682-9.
64. Korinek V, Barker N, Morin PJ, et al (1997). Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/-colon carcinoma. Science, 275, 1784-7.
65. Korn T, Bettelli E, Oukka M, et al (2009). IL-17 and Th17 Cells. Annu Rev Immunol, 27, 485-517.
66. Korn T, Oukka M, Kuchroo V, et al (2007). Th17 cells: effector T cells with inflammatory properties. Semin Immunol, 19, 362-71.
67. Kozomara A, Griffiths-Jones S (2011). miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res, 39, 30.
68. Kundu JK, Surh YJ (2008). Inflammation: gearing the journey to cancer. Mutat Res, 659, 15-30.
69. Kusaba T, Nakayama T, Yamazumi K, et al (2005). Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol, 58, 833-8.
70. Kusaba T, Nakayama T, Yamazumi K, et al (2006). Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep, 15, 1445-51.
71. Lakatos PL, Lakatos L (2008). Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol, 14, 3937-47.
72. Lassmann S, Schuster I, Walch A, et al (2007). STAT3 mRNA and protein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferation. J Clin Pathol, 60, 173-9.
73. Lee H, Herrmann A, Deng JH, et al (2009). Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell, 15, 283-93.
74. Lima RT, Busacca S, Almeida GM, et al (2011). MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer, 47, 163-74.
75. Lin L, Deangelis S, Foust E, et al (2010). A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells. Mol Cancer, 9, 217.
76. Lin L, Fuchs J, Li C, et al (2011). STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH(+)/CD133(+) stem cell-like human colon cancer cells. Biochem Biophys Res Commun, 416, 246-51.
77. Lu T, Stark GR (2004). Cytokine overexpression and constitutive NFkappaB in cancer. Cell Cycle, 3, 1114-7.
78. Mantovani A, Allavena P, Sica A, et al (2008). Cancer-related inflammation. Nature, 454, 436-44.
79. Maynard CL, Weaver CT (2009). Intestinal effector T cells in health and disease. Immunity, 31, 389-400.
80. McGeachy MJ, Cua DJ (2008). Th17 cell differentiation: the long and winding road. Immunity, 28, 445-53.
81. McKay CJ, Glen P, McMillan DC (2008). Chronic inflammation and pancreatic cancer. Best Pract Res Clin Gastroenterol, 22, 65-73.
82. Mitsuyama K, Toyonaga A, Sasaki E, et al (1995). Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut, 36, 45-9.
83. Monteleone G, Monteleone I, Fina D, et al (2005). Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology, 128, 687-94.
84. Mudter J, Neurath MF (2007). IL-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis, 13, 1016-23.
85. Neuman MG (2007). Immune dysfunction in inflammatory bowel disease. Transl Res, 149, 173-86.
86. Oberg AL, French AJ, Sarver AL, et al (2011). miRNA expression in colon polyps provides evidence for a multihit model of colon cancer. PLoS ONE, 6, 620465.
87. Ogura H, Murakami M, Okuyama Y, et al (2008). Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity, 29, 628-36.
88. Okayasu I, Ohkusa T, Kajiura K, et al (1996). Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut, 39, 87-92.
89. Pandurangan AK (2013). Potential Targets for Prevention of Colorectal Cancer: a Focus on PI3K/Akt/mTOR and Wnt Pathways. Asian Pac J Cancer Prev, 14, 2201-5.
90. Pandurangan AK, Ananda Sadagopan SK, Dharmalingam P et al (2013). Luteolin, a bioflavonoid inhibits Azoxymethane-induced colorectal cancer through Nrf2 signaling. Toxicol Mech Methods, 24, 13-20.
91. Pandurangan AK, Dharmalingam P, Ananda Sadagopan SK, et al (2012). Effect of luteolin on the levels of glycoproteins during azoxymethane-induced colon carcinogenesis in mice. Asian Pac J Cancer Prev, 13, 1569-73.
92. Petroulakis E, Mamane Y, Le Bacquer O,et al (2006). mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer, 94, 195-9.
93. Pikarsky E, Porat RM, Stein I, et al (2004). NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature, 431, 461-6.
94. Reddy BS (2004). Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. Environ Mol Mutagen, 44, 26-35.
95. Reedijk M, Odorcic S, Zhang H, et al (2008). Activation of Notch signaling in human colon adenocarcinoma. Int J Oncol, 33, 1223-9.
96. Riemenschneider MJ, Betensky RA, Pasedag SM, et al (2006). AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res, 66, 5618-23.
97. Robertson GP (2005). Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev, 24, 273-85.
98. Rose-John S, Mitsuyama K, Matsumoto S, et al (2009). Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease. Curr Pharm Des, 15, 2095-103.
99. Rubie C, Frick VO, Pfeil S, et al (2007). Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer. World J Gastroenterol, 13, 4996-5002.
100. Sakamoto K, Maeda S, Hikiba Y, et al (2009). Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res, 15, 2248-58.
101. Sartor RB (2006). Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol, 3, 390-407.
102. Sarver AL, French AJ, Borralho PM, et al (2009). Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer, 9, 401.
103. Scheid MP, Woodgett JR (2003). Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett, 546, 108-12.
104. Scheller J, Ohnesorge N, Rose-John S (2006). Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol, 63, 321-9.
105. Schottelius AJ, Dinter H (2006). Cytokines, NF-kappaB, microenvironment, intestinal inflammation and cancer. Cancer Treat Res, 130, 67-87.
106. Schroeter EH, Kisslinger JA, Kopan Rn (1998). Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature, 393, 382-6.
107. Seidelin JB, Nielsen OH (2005). Continuous cytokine exposure of colonic epithelial cells induces DNA damage. Eur J Gastroenterol Hepatol, 17, 363-9.
108. Seo HS, Choi HS, Kim SR, et al (2012). Apigenin induces apoptosis via extrinsic pathway, inducing p53 and inhibiting STAT3 and NFkappaB signaling in HER2-overexpressing breast cancer cells. Mol Cell Biochem, 366, 319-34.
109. Shafie NH, Mohd Esa N, Ithnin H, et al (2013). Prophylactic Inositol Hexaphosphate (IP6) inhibits colon cancer through involvement of Wnt/β-catenin and COX-2 pathway. BioMed Res Int, 2013, 681027.
110. Shanmugam MK, Rajendran P, Li F, et al (2011). Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice. J Mol Med, 89, 713-27.
111. Sheng H, Shao J, Williams CS, et al (1998). Nuclear translocation of beta-catenin in hereditary and carcinogen-induced intestinal adenomas. Carcinogenesis, 19, 543-9.
112. Sohn OS, Ishizaki H, Yang CS, et al (1991). Metabolism of azoxymethane, methylazoxymethanol and N-nitrosodimethylamine by cytochrome P450IIE1. Carcinogenesis, 12, 127-31.
113. Solinas G, Marchesi F, Garlanda C, et al (2010). Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev, 29, 243-8.
114. Sparks AB, Morin PJ, Vogelstein B, et al (1998). Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res, 58, 1130-4.
115. Steinman L (2007). A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med, 13, 139-45.
116. Stolfi C, Rizzo A, Franze E, et al (2011). Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J Exp Med, 208, 2279-90.
117. Suzui M, Ushijima T, Dashwood RH, et al (1999). Frequent mutations of the rat beta-catenin gene in colon cancers induced by methylazoxymethanol acetate plus 1-hydroxyanthraquinone. Mol Carcinog, 24, 232-7.
118. Suzuki A, Hanada T, Mitsuyama K, et al (2001). CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med, 193, 471-81.
119. Takahashi M, Fukuda K, Sugimura T, et al (1998). Beta-catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumors. Cancer Res, 58, 42-6.
120. Tenesa A, Dunlop MG (2009). New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet, 10, 353-8.
121. Tetsu O, McCormick F (1999). Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature, 398, 422-6.
122. Thiem S, Pierce TP, Palmieri M, et al (2013). mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. J Clin Invest, 123, 767-81.
123. Tian Y, Ye Y, Gao W, et al (2011). Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway. Int J Colorectal Dis, 26, 13-22.
124. Tyagi A, Singh RP, Ramasamy K, et al (2009). Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev Res, 2, 74-83.
125. Ullman TA, Itzkowitz SH (2011). Intestinal inflammation and cancer. Gastroenterology, 140, 1807-16.
126. Van Kemseke C, Belaiche J, Louis E (2000). Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission. Int J Colorectal Dis, 15, 206-10.
127. Villanueva A, Alsinet C, Yanger K, et al (2012). Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology, 143, 1660-9.
128. Wang B, Xiao Z, Chen B, et al (2008). Nogo-66 promotes the differentiation of neural progenitors into astroglial lineage cells through mTOR-STAT3 pathway. PLoS ONE, 3, 1856.
129. Wang Z, Jin H, Xu R, et al (2009). Triptolide downregulates Rac1 and the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression. Exp Mol Med, 41, 717-27.
130. Ward JM (1974). Morphogenesis of chemically induced neoplasms of the colon and small intestine in rats. Lab Invest, 30, 505-13.
131. Wodarz A, Nusse R (1998). Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol, 14, 59-88.
132. Yan S, Zhou C, Zhang W, et al (2008). beta-Catenin/TCF pathway upregulates STAT3 expression in human esophageal squamous cell carcinoma. Cancer Lett, 271, 85-97.
133. Yang Y, Yan X, Duan W, et al (2013). Pterostilbene Exerts Antitumor Activity via the Notch1 Signaling Pathway in Human Lung Adenocarcinoma Cells. PLoS ONE, 8, 62652.
134. Yu H, Jove R (2004). The STATs of cancer-new molecular targets come of age. Nat Rev Cancer, 4, 97-105.
135. Yu H, Kortylewski M, Pardoll D (2007). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol, 7, 41-51.
136. Yu H, Pardoll D, Jove R (2009). STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer, 9, 798-809.
137. Zhang HY, Spechler SJ, Souza RF (2009). Esophageal adenocarcinoma arising in Barrett esophagus. Cancer Lett, 275, 170-7.
138. Zhong Z, Wen Z, Darnell JE, Jr (1994). Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science, 264, 95-8.
139. Zhou J, Wulfkuhle J, Zhang H, et al (2007). Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A, 104, 16158-63.
140. Zhu H, Zhou X, Redfield S, et al (2013). Elevated Jagged-1 and Notch-1 expression in high grade and metastatic prostate cancers. Am J Transl Res, 5, 368-78.